In our work, polylactic-co-glycolic acids (PLGA)
Purasorb PDLG5002 and PDLG7502 (Corbion Purac, Amsterdam, The Netherlands) with an inherent viscosity midpoint of 0.2 dL/g and a lactic-to-glycolic-acid monomer ratio of 50:50 and 75:25, respectively, were used as a raw polymeric material. Both copolymers are supplied in the form of white to light tan-colored granules (1–3 mm across) and are primarily used in biomedical and drug delivery applications [32 ].
Prior to the experiments, initial PLGA granules were thoroughly grinded by a rotary cryomill Model LZM-1M (OLIS, Moscow, Russia) together with solid carbon dioxide (as a cooling agent). The ground polymer powders were then sifted through the Model CB-04 (Vibrotekhnika, St. Petersburg, Russia) calibrated sieve set 50 μm × 50 μm and 100 μm × 100 μm in mesh size to produce a 50–100 μm polymer particle fraction for further use.
The initial levofloxacin substance (CAS Number: 138199-71-0; Sigma-Aldrich, St. Louis, MO, USA) (
Figure 1, left) was presented as a fine powder with a mean particle size of ca. 5 to 100 μm (
Figure 1, right).
Chemically pure carbon dioxide (99.98%, NIIKM Ltd., Moscow, Russia) and trifluoromethane (99.8%, Rushimprom Corp., Moscow, Russia) were used as PLGA plasticizing and foaming agents without any additional purification.
Antonov E.N., Andreevskaya S.N., Bocharova I.V., Bogorodsky S.E., Krotova L.I., Larionova E.E., Mariyanats A.O., Mishakov G.V., Smirnova T.G., Chernousova L.N, & Popov V.K. (2022). PLGA Carriers for Controlled Release of Levofloxacin in Anti-Tuberculosis Therapy. Pharmaceutics, 14(6), 1275.